Monoclonal antibody therapeutics are an important tool that can improve outcomes for residents with COVID and reduce the risk of developing COVID in those exposed. Recent experience in Massachusetts has shown that being well-prepared to use these therapeutics before your facility identifies a case or experiences an outbreak, is critical. This webinar reviews the use of these therapeutics in the long-term care setting and shares insights from a facility that has recently seen success with large scale administration.
EUA fact sheets for products referenced:
- Bamlanivimab and Etesevimab: bam-and-ete-eua-factsheet-hcp.pdf (lilly.com)
- Regeneron: treatment-covid19-eua-fact-sheet-for-hcp.pdf (regeneron.com)
- Sotrovimab: SOTROVIMAB-EUA.PDF (gskpro.com)
Selected resources from the HHS Combat COVID page: